{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:22:16Z","timestamp":1787494936693,"version":"build-2736575974"},"reference-count":48,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Discontinuation of long-term denosumab (Dmab) remains a major clinical challenge because of rebound activation of bone remodeling and increased vertebral fracture risk. Intravenous zoledronate (ZOL) is widely recommended as sequential therapy, although evidence after very prolonged Dmab exposure is limited. We report a patient who developed two rare adverse events\u2014acute hepatocellular injury and delayed inflammatory polyarthritis\u2014following a single ZOL infusion administered after 12 years of continuous Dmab treatment. The subsequent management of persistent rebound bone turnover with oral alendronate (ALN) highlights the therapeutic challenges encountered when repeat ZOL administration is not feasible. Methods: A 65-year-old woman with postmenopausal osteoporosis received a single 5 mg ZOL infusion 6 months after her final Dmab injection following 12 years of continuous therapy. Within 24 h, she developed a typical acute phase response. Three days later, marked hepatocellular injury was detected, characterized by substantial elevations in transaminases and gamma-glutamyl transferase, while viral and autoimmune hepatitis were excluded. Liver enzymes normalized within five days with supportive management. Thirty-two days after ZOL administration, she developed inflammatory polyarthritis in the absence of previous rheumatologic disease and with negative immunologic testing. Treatment with low-dose prednisone (5 mg\/day) resulted in rapid clinical and biochemical remission. At 6 months, bone turnover markers remained markedly elevated (CTX 0.82 ng\/mL, P1NP 95 ng\/mL), indicating insufficient suppression of rebound bone turnover after Dmab discontinuation. Because of the adverse events, the patient declined repeat ZOL administration. Results: Weekly oral alendronate (ALN) (70 mg) was initiated and was associated with partial suppression of bone turnover markers. Despite a decline in bone mineral density (BMD) of approximately 5% at both the lumbar spine and total hip over 12 months, BMD remained within the osteopenic range, and no new fragility fractures occurred during follow-up. Conclusions: This case illustrates two rare sequential immune-mediated adverse events following ZOL infusion and underscores the therapeutic challenges of managing Dmab discontinuation after long-term treatment when repeat ZOL administration is contraindicated. Sequential intravenous ZOL and oral ALN therapy was associated with partial suppression of bone turnover markers and protection from incident fractures during follow-up, despite a modest decline in BMD of approximately 5%.<\/jats:p>","DOI":"10.3390\/jcm15145443","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:53:58Z","timestamp":1783932838000},"page":"5443","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges in Sequential Antiresorptive Therapy After Long-Term Denosumab Discontinuation: A Case Report and Narrative Review of the Literature"],"prefix":"10.3390","volume":"15","author":[{"given":"Maria-Evangelia","family":"Koloutsou","sequence":"first","affiliation":[{"name":"Endocrinology Unit, 1st Department of Propaedeutic and Internal Medicine, School of Medicine, Laikon University Hospital of Athens, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina Despina","family":"Pieper","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, 1st Department of Propaedeutic and Internal Medicine, School of Medicine, Laikon University Hospital of Athens, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9629-7346","authenticated-orcid":false,"given":"Maria","family":"Mateniadou","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, 1st Department of Propaedeutic and Internal Medicine, School of Medicine, Laikon University Hospital of Athens, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Papapanagiotou","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 15784 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, 424 General Military Hospital, 56429 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou St., 11525 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-3692","authenticated-orcid":false,"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, 1st Department of Propaedeutic and Internal Medicine, School of Medicine, Laikon University Hospital of Athens, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"115390","DOI":"10.1016\/j.bone.2020.115390","article-title":"Zoledronate","volume":"137","author":"Reid","year":"2020","journal-title":"Bone"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tsourdi, E., Zillikens, M.C., Meier, C., Body, J.-J., Rodriguez, E.G., Anastasilakis, A.D., Abrahamsen, B., McCloskey, E., Hofbauer, L.C., and Gua\u00f1abens, N. (2020). Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS. J. Clin. Endocrinol. Metab.","DOI":"10.1210\/clinem\/dgaa756"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral Fractures after Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: A Randomized Trial","volume":"35","author":"Solling","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider","volume":"130","author":"Fund","year":"2020","journal-title":"Bone"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/M20-0882","article-title":"Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis: A Population-Based Cohort Study","volume":"173","author":"Lyu","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","article-title":"The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"138","author":"Makras","year":"2020","journal-title":"Bone"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/cpt.70088","article-title":"Therapeutic Strategies of Denosumab Sequential Therapy: A Four-Armed Randomized Controlled Trial","volume":"119","author":"Yen","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"117600","DOI":"10.1016\/j.bone.2025.117600","article-title":"Treating osteoporosis with denosumab or bisphosphonates in the long term: Facts, uncertainties and assumptions. A narrative review by the clinical action group of the European Calcified Tissue Society (ECTS)","volume":"200","author":"Naciu","year":"2025","journal-title":"Bone"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study","volume":"36","author":"Solling","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone Mineral Density After Transitioning From Denosumab to Alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: A retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.bone.2012.02.006","article-title":"Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass","volume":"50","author":"Anastasilakis","year":"2012","journal-title":"Bone"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00198-024-07213-2","article-title":"One versus 2 years of alendronate following denosumab: The CARD extension","volume":"35","author":"Tsai","year":"2024","journal-title":"Osteoporos. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/EJE-21-0157","article-title":"Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence","volume":"185","author":"Grassi","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Anastasilakis, A.D., Makras, P., Yavropoulou, M.P., Tabacco, G., Naciu, A.M., and Palermo, A. (2021). Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010152"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14740338.2021.1867102","article-title":"Questions and facts regarding denosumab discontinuation among postmenopausal women","volume":"20","author":"Makras","year":"2021","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3803\/EnM.2024.2125","article-title":"Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use","volume":"40","author":"Ha","year":"2025","journal-title":"Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Makras, P., Anastasilakis, A.D., Palermo, A., Naciu, A.M., Polyzos, S.A., Georgakopoulou, D., Papatheodorou, A., Savvidis, M., Papapoulos, S., and Yavropoulou, M.P. (2026). Alendronate for 6 or 12 months following denosumab discontinuation in women with postmenopausal osteoporosis: A prospective observational study. J. Bone Miner Res.","DOI":"10.1093\/jbmr\/zjag103"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00223-021-00884-7","article-title":"Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study","volume":"109","author":"Shiraki","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"luaf046","DOI":"10.1210\/jcemcr\/luaf046","article-title":"Drug-Induced Liver Injury after Zoledronic Acid Infusion and Literature Review","volume":"3","author":"Boldt","year":"2025","journal-title":"JCEM Case Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00198-010-1230-5","article-title":"Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget\u2019s disease of bone","volume":"22","author":"Polyzos","year":"2011","journal-title":"Osteoporos. Int."},{"key":"ref_31","first-page":"115","article-title":"Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis","volume":"12","author":"Lu","year":"2013","journal-title":"EXCLI J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40001-015-0161-1","article-title":"Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis","volume":"20","author":"Jiang","year":"2015","journal-title":"Eur. J. Med. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/ijem.ijem_484_21","article-title":"Transient Hepatitis Secondary to Zoledronic Acid in a Woman with Sheehan Syndrome","volume":"26","author":"Laway","year":"2022","journal-title":"Indian. J. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000479314","article-title":"Drug-Induced Autoimmune Hepatitis following Treatment with Zoledronic Acid","volume":"11","author":"Schneider","year":"2017","journal-title":"Case Rep. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00198-009-1123-7","article-title":"Flare-up of hand osteoarthritis caused by zoledronic acid infusion","volume":"21","author":"Neves","year":"2010","journal-title":"Osteoporos. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.5001\/omj.2025.08","article-title":"Osteoarthritis Flare-up Secondary to Zoledronic Acid Infusion: A Case Report","volume":"40","year":"2025","journal-title":"Oman Med. J."},{"key":"ref_37","first-page":"e15627","article-title":"A Case of Pseudogout Following Zoledronic Acid Administration","volume":"13","author":"Hill","year":"2021","journal-title":"Cureus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.joms.2011.06.215","article-title":"Suppurative arthritis of the temporomandibular joint associated with bisphosphonate: A case report","volume":"70","author":"Enomoto","year":"2012","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.rhu.0000221796.06383.4e","article-title":"Bisphosphonate-associated arthritis","volume":"12","author":"Seyler","year":"2006","journal-title":"J. Clin. Rheumatol."},{"key":"ref_40","first-page":"69","article-title":"Severe polyarthritis secondary to zolendronic acid: A case report and literature review","volume":"12","author":"White","year":"2015","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_41","first-page":"e44892","article-title":"A Rare Case of Acute Calcium Pyrophosphate Deposition Disease Following Zoledronic Acid Infusion","volume":"15","author":"Florica","year":"2023","journal-title":"Cureus"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"luae199","DOI":"10.1210\/jcemcr\/luae199","article-title":"Bilateral Knee Effusions Secondary to Zoledronic Acid Infusion","volume":"2","author":"Wei","year":"2024","journal-title":"JCEM Case Rep."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Alonso Perez, J.L., Martin Perez, S., Battaglino, A., Villafane, J.H., Alonso-Sal, A., and Sanchez Romero, E.A. (2021). An Up-Date of the Muscle Strengthening Exercise Effectiveness in Postmenopausal Women with Osteoporosis: A Qualitative Systematic Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112229"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3803\/EnM.2021.1369","article-title":"Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature","volume":"37","author":"Tay","year":"2022","journal-title":"Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jbmr\/zjaf037","article-title":"Denosumab discontinuation in the clinic: Implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures","volume":"40","author":"Kumar","year":"2025","journal-title":"J. Bone Miner. Res."},{"key":"ref_46","first-page":"329","article-title":"Management of Postmenopausal Osteoporosis","volume":"66","author":"Reid","year":"2026","journal-title":"Endocr. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40520-025-02973-1","article-title":"Advancing care: Optimizing osteoporosis treatment in the older and oldest old population","volume":"37","author":"Panait","year":"2025","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e110765","DOI":"10.1136\/bmjopen-2025-110765","article-title":"PhyCARE reporting guidelines for physiotherapy case reports: A consensus-based development","volume":"16","author":"Naqvi","year":"2026","journal-title":"BMJ Open"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5443\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:11:52Z","timestamp":1783933912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":48,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145443"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145443","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]}}}